Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic Melanoma.

ABSTRACT: Melanoma's incidence is increasing, and elderly people could be significantly impacted since the majority occurs in people over 65 years of age. Combined BRAF and MEK targeted therapies (TT) are current standard regimen for BRAF mutated metastatic melanoma (MM). Except for subgroups of pivotal trials, little data are available for TT in this population. Outcomes were explored in real life patients from MelBase, a French multicentric biobank dedicated to the prospective follow-up of unresectable stage III or IV melanoma. Patients treated by BRAF TT and/or MEK TT combined or not, were included from 2013 to 2017 in 2 groups: group 1 ≤ 65-year-old (yo), group 2 > 65 yo, analyzed for tolerance and efficacy. 353 patients were included: 231 in group 1, 122 in group 2. Median follow-up was 12 mont

SUBMITTER: Becquart O 

PROVIDER: S-EPMC8235702 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature